Arbutus Biopharma Logo
Tekmira Provides Periodic Update to Litigation
20 oct. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 20, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Arbutus Biopharma Logo
Tekmira and Collaborators Demonstrate Efficacy of RNAi Against Hepatitis C Virus
12 sept. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Tekmira to Present at the Stifel Nicolaus Annual Healthcare Conference
01 sept. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Acquires Worldwide Exclusive License to Novel RNAi Platform
25 août 2011 08h15 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Announces Second Quarter 2011 Results
11 août 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 11, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its...
Arbutus Biopharma Logo
Tekmira Announces Additional Clinical Trial of TKM-PLK1 with the U.S. National Cancer Institute
09 août 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, along with its...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Second Quarter 2011 Operating Results and Corporate Update
04 août 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Reports Expected Answer and Amended Counterclaim is Filed by Alnylam
29 juin 2011 08h30 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 29, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, reports that Alnylam...
Arbutus Biopharma Logo
Tekmira Closes $5.1 Million Public Offering
16 juin 2011 08h48 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 16, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, has closed its...
Arbutus Biopharma Logo
Tekmira Prices Public Offering
09 juin 2011 08h59 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 9, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today it has...